Search research articles
Contact Us
Filters
Showing results (81-90 of 137) with videos related to
Page
of 14
Sort By:
Blood Research
|
October 13, 2015
Prediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous transplantation
Hong Ghi Lee, Sung-Yong Kim, Inho Kim, et al.
The Korean Journal of Internal Medicine
|
June 19, 2023
Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study
Dong Won Baek, Han-Seung Park, Sang Kyun Sohn, et al.
Bone Marrow Transplantation
|
July 31, 2019
Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma
Yoo Jin Lee, Joon Ho Moon, Sang Kyun Sohn, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
October 22, 2013
High-dose etoposide plus granulocyte colony-stimulating factor as an effective chemomobilization regimen for autologous stem cell transplantation in patients with non-Hodgkin Lymphoma previously treated with CHOP-based chemotherapy: a study from the Consortium for Improving Survival of Lymphoma
Shin Young Hyun, June-Won Cheong, Soo-Jeong Kim, et al.
British Journal of Haematology
|
July 3, 2026
Prospective, multicentre phase II study to evaluate the clinical benefit of reduced-dose lenalidomide and dexamethasone based on frailty stratification in elderly, unfit patients with newly diagnosed multiple myeloma
Sung-Hoon Jung, Dajung Kim, Je-Jung Lee, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation
|
June 2, 2020
Treatment with intravenous busulfan, melphalan, and etoposide followed by autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a multicenter study from the consortium for improving survival of lymphoma
Kyoung Ha Kim, Won Seog Kim, Seok Jin Kim, et al.
Journal of Korean Medical Science
|
January 24, 2013
Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation
Ho Sup Lee, Yang Soo Kim, Kihyun Kim, et al.
BMC Cancer
|
November 12, 2019
Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma
Seok Jin Kim, Dok Hyun Yoon, Hye Jin Kang, et al.
Blood Research
|
July 16, 2014
R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma
Hong Ghi Lee, Yunsuk Choi, Sung-Yong Kim, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 8, 2019
Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome
Sungwoo Park, Dong Won Baek, Sang Kyun Sohn, et al.
Page
of 14
Search research articles
Search
Showing results (81-90 of 137) with videos related to
Sort By:
Page
of 14
Blood Research
|
October 13, 2015
Prediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous transplantation
Hong Ghi Lee, Sung-Yong Kim, Inho Kim, et al.
The Korean Journal of Internal Medicine
|
June 19, 2023
Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study
Dong Won Baek, Han-Seung Park, Sang Kyun Sohn, et al.
Bone Marrow Transplantation
|
July 31, 2019
Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma
Yoo Jin Lee, Joon Ho Moon, Sang Kyun Sohn, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
October 22, 2013
High-dose etoposide plus granulocyte colony-stimulating factor as an effective chemomobilization regimen for autologous stem cell transplantation in patients with non-Hodgkin Lymphoma previously treated with CHOP-based chemotherapy: a study from the Consortium for Improving Survival of Lymphoma
Shin Young Hyun, June-Won Cheong, Soo-Jeong Kim, et al.
British Journal of Haematology
|
July 3, 2026
Prospective, multicentre phase II study to evaluate the clinical benefit of reduced-dose lenalidomide and dexamethasone based on frailty stratification in elderly, unfit patients with newly diagnosed multiple myeloma
Sung-Hoon Jung, Dajung Kim, Je-Jung Lee, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation
|
June 2, 2020
Treatment with intravenous busulfan, melphalan, and etoposide followed by autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a multicenter study from the consortium for improving survival of lymphoma
Kyoung Ha Kim, Won Seog Kim, Seok Jin Kim, et al.
Journal of Korean Medical Science
|
January 24, 2013
Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation
Ho Sup Lee, Yang Soo Kim, Kihyun Kim, et al.
BMC Cancer
|
November 12, 2019
Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma
Seok Jin Kim, Dok Hyun Yoon, Hye Jin Kang, et al.
Blood Research
|
July 16, 2014
R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma
Hong Ghi Lee, Yunsuk Choi, Sung-Yong Kim, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 8, 2019
Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome
Sungwoo Park, Dong Won Baek, Sang Kyun Sohn, et al.
Page
of 14